Sofe-m was acquired by Lilly as part of its 2023 takeover of French biotech Mablink Bioscience and its PSARLink ADC development platform, which is designed to mask the cytotoxic payload carried by the ...
A drug at the heart of Johnson & Johnson's $3 billion takeover of Halda last year, JNJ-6143, has shown promise in an ...
Two drugs hoping to muscle in Amgen's first-to-market DLL3-targeting drug Imdelltra – from Zai Lab and Ideaya – have new ...
In the new guidance, the agency has concluded that AI-Rad Companion Prostate MR, DeepHealth Prostate, ProstatID, Prostate ...
The most consequential changes in cancer biology can often occur before they become visible on a scan. Yet, modern cancer ...
An overview of the NHS’s AI-Assisted Discharge Summarisation (AADS) project and what it takes to move AI beyond the pilot ...
As the European Society for Medical Oncology 2026 Congress commences in Madrid, pharmaphorum invited Syncromune Executive ...
Hibsago, has been approved in the US, its second major market after Japan, giving patients hope of a functional cure without ...
Julia Jakl is VP and Business Unit Head, Oncology UK at GSK. With more than a decade of experience across oncology and ...
Waterhouse is due to take the helm of CSL on 1st February next year, around a year after Paul McKenzie abruptly departed the ...
A year after signing a first deal with Hansoh worth up to $1.45 billion, Roche has returned for another that could be more ...
Merck KGaA has reached a deal to acquire UK-based Silence Therapeutics in an all-cash, $1.3 billion deal that will boost its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results